Want to see SYK full AI Analyst Report?
Top Page
Stryker
(NYSE:SYK)
Select Model
Select Model
Rating:67Neutral
Price Target:
$343.00
▼(-0.09% Downside)
Action:Reiterated
Date:06/27/26
SYK scores well on underlying business quality and cash generation (strong multi-year revenue expansion, high gross margins, and growing operating/FCF), but the overall score is tempered by premium valuation (P/E 36.2), mixed technical positioning (below 100/200-day averages), and near-term operational/margin pressures discussed on the earnings call despite reaffirmed full-year guidance.
Positive Factors
Scale & Gross Margins
Stryker's materially larger revenue base and sustained ~60–64% gross margins indicate durable scale and pricing power in hospitals and surgical settings. Scale supports R&D, distribution and marketing investments that reinforce competitive position and defend margins over the medium term.
Negative Factors
Margin Compression
A sustained decline from peak net margins signals structural cost pressures (tariffs, absorption from disruptions, higher interest) that can erode profitability even as revenue grows. If cost headwinds persist, margin recovery may be slow and constrain cash flow expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Scale & Gross Margins
Stryker's materially larger revenue base and sustained ~60–64% gross margins indicate durable scale and pricing power in hospitals and surgical settings. Scale supports R&D, distribution and marketing investments that reinforce competitive position and defend margins over the medium term.
Read all positive factors
Stryker Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down Stryker’s revenue by region to show geographic concentration, sensitivity to local healthcare spending and procedure volumes, and which markets are fueling future expansion or posing risk.
Breaks down Stryker’s revenue by region to show geographic concentration, sensitivity to local healthcare spending and procedure volumes, and which markets are fueling future expansion or posing risk.
Data provided by:
The Fly
The FlyStryker (SYK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$126.42B
Dividend Yield0.95%
Average Volume (3M)2.42M
Price to Earnings (P/E)37.8
Beta (1Y)0.55
Revenue Growth8.84%
EPS Growth16.34%
CountryUS
Employees56,000
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)8.73
Shares Outstanding383,360,750
10 Day Avg. Volume2,267,526
30 Day Avg. Volume2,421,620
Financial Highlights & Ratios
PEG Ratio5.16
Price to Book (P/B)5.99
Price to Sales (P/S)5.35
P/FCF Ratio31.36
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue5.06
Enterprise Value/Gross Profit7.94
Enterprise Value/Ebitda20.74
Forecast
1Y Price Target
$384.81Price Target Upside12.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
EPS Forecast (FY)14.98
Revenue Forecast (FY)$27.27B
Stryker Business Overview & Revenue Model
Company Description
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including ...
How the Company Makes Money
Stryker makes money primarily by selling medical devices, implants, capital equipment, and related consumables and services to hospitals, surgery centers, and other healthcare providers globally. Its revenue model combines: (1) recurring procedure...
Stryker Earnings Call Summary
Earnings Call Date:Apr 30, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Positive
The call mixed a significant near-term operational setback—the late-quarter cyber incident that materially distorted Q1 results, pressured margins and reduced EPS—with several strong positives: rapid operational recovery, record Mako installations and robust robotic momentum, continued healthy underlying demand, strategic reorganization (Ortho Tech), active M&A (AVS) and maintained full-year guidance (organic sales growth 8.0%–9.5%, adjusted EPS $14.90–$15.10). Management expects most lost Q1 sales to be realized through the rest of the year, with catch-up skewed to the back half, and emphasized customer/employee support and successful recovery efforts.Positive Updates
Organic Sales Growth Despite Disruption
Q1 organic net sales growth of 2.4% worldwide, with 1.9% growth in the U.S. and 3.9% internationally. Management emphasized underlying demand remained healthy across businesses despite the cyber incident.
Negative Updates
Significant Cyber Incident Disruption
Late-quarter cyber incident caused global operational disruption, delayed shipments and revenue recognition, wiped devices, and required multi-week recovery efforts. The incident materially distorted Q1 results and delayed normal reporting detail.
Read all updates
Q1-2026 Updates
Positive
Negative
Organic Sales Growth Despite Disruption
Q1 organic net sales growth of 2.4% worldwide, with 1.9% growth in the U.S. and 3.9% internationally. Management emphasized underlying demand remained healthy across businesses despite the cyber incident.
Read all positive updates
Company Guidance
Stryker reiterated full‑year guidance despite the late‑quarter cyber incident, forecasting organic net sales growth of 8.0%–9.5% and full‑year adjusted net earnings per share of $14.90–$15.10, with adjusted other income and expense expected to be about $420 million and a full‑year effective tax rate of 15%–16%; management said most first‑quarter disruption will be recovered through the year with some revenue catch‑up in Q2 and more in H2, and that pricing should be modestly positive (with a slightly favorable FX/interest rate tailwind if rates hold and some anticipated tariff improvement). For Q1 they reported 2.4% organic sales growth (U.S. 1.9%, international 3.9%), pricing +0.3%, FX +1.6%, adjusted EPS of $2.60 (down $0.24 or 8.5% YoY), adjusted gross margin 63.6% (‑190 bps) and adjusted operating margin 21.1% (‑180 bps); YTD cash from operations was $581 million, gross debt/EBITDA was ~2.1x, and management continues to target healthy margin and cash conversion (roughly 70%–80% FCF conversion).Stryker Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
74
Positive
Cash Flow
77
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 25.27B | 25.12B | 22.59B | 20.50B | 18.45B | 17.11B |
| Gross Profit | 16.09B | 16.07B | 13.98B | 12.49B | 11.04B | 10.71B |
| EBITDA | 6.16B | 6.31B | 4.94B | 5.06B | 4.02B | 3.61B |
| Net Income | 3.34B | 3.25B | 2.99B | 3.17B | 2.36B | 1.99B |
Balance Sheet | ||||||
| Total Assets | 46.29B | 47.84B | 42.97B | 39.91B | 36.88B | 34.63B |
| Cash, Cash Equivalents and Short-Term Investments | 2.96B | 4.10B | 4.49B | 3.05B | 1.93B | 3.02B |
| Total Debt | 15.23B | 16.36B | 14.12B | 13.49B | 13.53B | 12.90B |
| Total Liabilities | 23.31B | 25.42B | 22.34B | 21.32B | 20.27B | 19.75B |
| Stockholders Equity | 22.98B | 22.42B | 20.63B | 18.59B | 16.62B | 14.88B |
Cash Flow | ||||||
| Free Cash Flow | 4.57B | 4.28B | 3.49B | 3.14B | 2.04B | 2.74B |
| Operating Cash Flow | 5.38B | 5.04B | 4.24B | 3.71B | 2.62B | 3.26B |
| Investing Cash Flow | -915.00M | -4.87B | -3.00B | -962.00M | -2.92B | -859.00M |
| Financing Cash Flow | -3.93B | 113.00M | -525.00M | -1.59B | -749.00M | -2.37B |
Stryker Technical Analysis
Positive
343.32
Price Trends
308.39
Positive
327.86
Positive
344.43
Negative
Market Momentum
5.39
Negative
59.35
Neutral
74.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYK, the sentiment is Positive. The current price of 343.32 is above the 20-day moving average (MA) of 316.80, above the 50-day MA of 308.39, and below the 200-day MA of 344.43, indicating a neutral trend. The MACD of 5.39 indicates Negative momentum. The RSI at 59.35 is Neutral, neither overbought nor oversold. The STOCH value of 74.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SYK.
Stryker Risk Analysis
Stryker disclosed 29 risk factors in its most recent earnings report. Stryker reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Stryker Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $17.67B | 23.60 | 6.01% | 1.05% | 9.23% | -14.66% | |
71 Outperform | $53.09B | 48.79 | 10.55% | ― | 13.81% | 22.90% | |
68 Neutral | $66.54B | 18.65 | 14.82% | ― | 17.44% | 74.36% | |
68 Neutral | $107.36B | 22.37 | 9.92% | 2.76% | 8.43% | 3.17% | |
67 Neutral | $126.42B | 37.78 | 15.10% | 0.95% | 8.84% | 16.34% | |
62 Neutral | $163.61B | 26.09 | 12.20% | 1.88% | 6.59% | -53.44% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
SYK
Stryker
329.78
-57.73
-14.90%
ABT
Abbott Laboratories
93.93
-35.46
-27.40%
BSX
Boston Scientific
44.77
-59.56
-57.09%
EW
Edwards Lifesciences
92.21
13.93
17.80%
MDT
Medtronic
83.87
-3.03
-3.49%
ZBH
Zimmer Biomet Holdings
91.34
-1.54
-1.66%
Stryker Corporate Events
Business Operations and StrategyDividendsFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
Stryker Reorganizes Orthopaedics Into New Ortho Tech Business
Positive
Jun 26, 2026
In the first quarter of 2026, Stryker reorganized its Orthopaedics operations by creating an Ortho Tech business that combines orthopaedic instruments from its Instruments unit with the Mako robotics and enabling technologies portfolio, aiming to ...
Executive/Board Changes
Stryker Announces Chief Accounting Officer Retirement and Successor
Neutral
May 20, 2026
Stryker announced on May 20, 2026 that Vice President and Chief Accounting Officer William E. Berry, Jr. will retire from his role effective September 1, 2026, and will serve as Advisor to the Chief Financial Officer until August 15, 2027 under a ...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Stryker Shareholders Reelect Board and Approve Governance Measures
Positive
May 8, 2026
At Stryker’s Annual Meeting of Shareholders on May 6, 2026, investors elected all ten board nominees, including Chair and CEO Kevin A. Lobo and director Ronda E. Stryker, to serve until the next annual meeting, with each candidate receiving ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.